Baseline characteristics of the two study groups (TAT group and DAT group)
| TAT group (n=110) | DAT group (n=73) | P -values | |
| Age, mean±SD, years | 61.41±12.06 | 60.27±9.88 | 0.505 |
| Male, n (%) | 90 (81.8%) | 53 (72.6%) | 0.140 |
| BMI, mean±SD, kg/m2 | 25.16±2.80 | 26.03±3.40 | 0.060 |
| Smoking, n (%) | 52 (47.3%) | 39 (53.4%) | 0.415 |
| CHD, n (%) | 16 (14.5%) | 16 (21.9%) | 0.199 |
| Diabetes, n (%) | 38 (34.5%) | 30 (41.1%) | 0.369 |
| Hypertension, n (%) | 76 (69.1%) | 54 (74.0%) | 0.476 |
| Prior cerebral infarction, n (%) | 82 (74.5%) | 49 (67.1%) | 0.276 |
| Hyperlipidemia, n (%) | 43 (39.1%) | 28 (38.4%) | 0.920 |
| Alcohol consumption, n (%) | 32 (29.1%) | 23 (31.5%) | 0.727 |
| Laboratory data | |||
| TC, mean±SD, mmol/L | 3.40±0.88 | 3.64±1.04 | 0.095 |
| PLT, mean±SD,×1012/L | 211.46±66.68 | 206.82±50.65 | 0.614 |
| ESR, median (IQR), mm/h | 6.00 (4.00–10.00) | 7.00 (3.75–14.00) | 0.406 |
| CRP, median (IQR), mg/L | 1.57 (0.68–3.35) | 1.90 (1.01–4.27) | 0.093 |
| HCY, median (IQR), mmol/L | 12.45 (10.67–18.95) | 11.70 (8.55–17.20) | 0.072 |
| LDL, mean±SD, mmol/L | 2.10±0.72 | 2.13±0.95 | 0.831 |
| PT, mean±SD, s | 11.22±2.30 | 10.74±0.73 | 0.088 |
| INR, mean±SD | 0.99±0.20 | 0.95±0.07 | 0.089 |
| APTT, mean±SD, s | 32.29±3.33 | 32.38±3.20 | 0.861 |
| GLU, mean±SD, mmol/L | 6.10±1.86 | 6.02±1.46 | 0.747 |
| HBA1C, mean±SD, % | 6.36±1.33 | 6.24±0.84 | 0.508 |
| RBC, mean±SD,×1012/L | 4.51±0.47 | 4.49±0.50 | 0.842 |
| Antiplatelet resistance | |||
| Aspirin, n (%) | 10 (9.1%) | 12 (16.4%) | 0.135 |
| Clopidogrel, n (%) | 106 (96.4%) | 68 (93.2%) | 0.487 |
| Both, n (%) | 6 (5.5%) | 7 (9.6%) | 0.320 |
| Stent features | |||
| Intracranial stent, n (%) | 62 (56.4%) | 42 (57.5%) | 0.876 |
| Extracranial stent, n (%) | 52 (47.3%) | 37 (50.7%) | 0.651 |
| Both, n (%) | 4 (3.6%) | 6 (8.2%) | 0.316 |
| Number of stents≥2, n (%) | 15 (13.6%) | 14 (19.2%) | 0.315 |
APTT, activated partial thromboplastin time; BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein; DAT, dual antiplatelet therapy; ESR, erythrocyte sedimentation rate; GLU, glucose; HbA1c, glycosylated hemoglobin; HCY, homocysteine; INR, International normalized ratio; LDL-C, low-density lipoprotein cholesterol; PLT, platelet; PT, prothrombin time; RBC, red blood cells; TAT, triple antiplatelet therapy; TC, total cholesterol.